CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 215 enrolled
Drug / intervention
None - Common practiceother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03959137
NCT03959137N/ACompleted
CompareCT.gov

BEPACT Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium: A Cross-sectional Study

MSD Belgium BVBA·observational·Posted May 22, 2019·Updated Sep 9, 2021

In Brief

An observational study evaluating None - Common practice for Stage IV Non-small Cell Lung Cancer. Completed, enrolled 215 participants across 21 sites.

Detailed Summary

The treatment landscape of metastatic non small cell lung cancer (NSCLC) is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years. New combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics. The link between patient and tumor characteristics in untreated stage IV non small cell lung cancer (NSCLC) patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Non-small Cell Lung Cancer
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 22, 2019
Enrollment StartJun 3, 2019
Primary CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7.1 years ago

Interventions

None - Common practiceother

None - Common practice